Abstract
Purpose
Methods
Findings
Implications
Key words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsReferences
- Endothelium and acute coronary syndromes.Clin Chem. 1998; 44: 1799-1808
- Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia.Expert Rev Cardiovasc Ther. 2003; 1: 495-505
- Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.Cardiovasc Drug Rev. 2002; 20: 303-328
World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization/International Society of Hypertension Statement on Management of Hypertension. 2003.
Boehringer Ingelheim. Micardis (telmisartan) [prescribing information]. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Micardis+Tabs/MICARDIS20-40-80mg.PDF. Accessed November 3, 2015.
- Telmisartan: a review of its use in the management of hypertension.Drugs. 2006; 66: 51-83
- Management of hypertension and dyslipidemia.Curr Hypertens Rep. 2006; 8: 489-496
- Evidence for a combined approach to the management of hypertension and dyslipidemia.Am J Hypertens. 2005; 18: 1249-1257
- Treatment with drugs to lower blood pressure and blood cholesterol based on an individual׳s absolute cardiovascular risk.Lancet. 2005; 365: 434-441
- The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.Cardiovasc Ther. 2012; 30: e234-e241
- Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.Drug Metab Dispos. 2008; 36: 2014-2023
- A perspective on efflux transport proteins in the liver.Clin Pharmacol Ther. 2012; 92: 599-612
- Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.Pharmacol Rev. 2011; 63: 157-181
AstraZeneca. Crestor (rosuvastatin) [prescribing information]. http://www1.astrazeneca-us.com/pi/crestor.pdf. Accessed November 3, 2015.
Crestor tablets. AccessdataFDA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/21366slr005lbl.pdf. Accessed June 3, 2016.
- Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans.Drug Metab Dispos. 2006; 34: 1109-1115
- Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide.Drug Metab Dispos. 2008; 36: 796-805
- Telmisartan pharmacokinetics in Japanese renal transplant recipients.Clin Chim Acta. 2009; 399: 83-87
Boehringer Ingelheim. Twynsta (telmisartan/amlodipine) [prescribing information]. www.accessdata.fda.gov/drugsatfda_docs/label/2014/022401s016lbl.pdf. Accessed November 3, 2015.
- Pharmacokinetics and pharmacodynamics of amlodipine.Cardiology. 1992; 80: 31-36
- Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension.Hypertens Res. 2005; 28: 223-227
- Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin.Int J Clin Pharmacol Ther. 2010; 48: 497-503
- Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine.Drug Metab Pharmacokinet. 2014; 29: 120-128
- Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.Ther Clin Risk Manag. 2014; 10: 17-26
- Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study.Clin Ther. 2014; 36: 1147-1158
Clinical Pharmacology And Biopharmaceutics Review(s) Application Number 22-401. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/22401s000clinpharmr.pdf. Accessed December 23, 2015.
- Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers.J Clin Pharmacol. 2000; 40: 1347-1354
- Ministry of Food and Drug Safety. Korean Good Clinical Practice Guideline. 2014.
World Medical Association. Declaration Of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/en/30publications/10policies/b3/. Accessed November 3, 2015.
Center for Drug Evaluation and Research (CDER), Food and Drug Administration, US Dept of Health and Human Services. Guidance for Industry Drug Interaction Studies: Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed June 3, 2016.
- Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients.Acta Pharmacol Sin. 2011; 32: 116-125
- Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge.J Cardiovasc Pharmacol. 2001; 38: 672-685
- Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension.J Clin Pharmacol. 2011; 51: 933-942
Clinical Pharmacology and Biopharmaceutics Review(S) Application Number 200175. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200175Orig1s000ClinPharmR.pdf. Accessed December 30, 2015.
- Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.J Int Med Res. 2000; 28: 149-167
- Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study.Pharmacol Res. 2005; 51: 445-452
